Low-Dose Palliative Radiotherapy for Cutaneous B- and T-Cell Lymphomas

Neelis, Karen J.; Schimmel, Erik C.; Vermeer, Maarten H.; Senff, Nancy J.; Willemze, Rein; Noordijk, Evert M.

doi:10.1016/j.ijrobp.2008.06.1918

Cited by 142 publications

(100 citation statements)

References 19 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The annual incidence of primary cutaneous lymphomas is estimated to be 1:100,000, of which CTCL is the most common type representing approximately 75% of cases [3,4]. CTCLs are non-Hodgkin's lymphomas characterized by the clonal proliferation of skin-invasive mature T-lymphocytes [3].…”

Section: Introductionmentioning

confidence: 99%

STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL

Verma

Davies

Long

et al. 2010

Cellular and Molecular Biology Letters

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin’s lymphomas resulting from clonal expansion and localization of malignant T-lymphocytes to the skin. CTCL cells have defective apoptosis. Signal transducers and activators of transcription (STAT) are a family of transcription factors known to play important roles in the development and progression of several human cancers by promoting cell proliferation and protecting against apoptosis. In this study, we investigated the specific role of STAT3, a major component of the STAT family, in growth and survival of human CTCL cell line Hut78. Western immunoblot analysis showed elevated expression of STAT3 and phospho-STAT3(Y705) in human CTCL cells as compared to freshly isolated peripheral blood lymphocytes (PBLs). Specific knockdown of STAT3 expression in Hut78 cells by RNA interference induced morphological and biochemical changes indicating apoptotic cell death. Moreover, STAT3 inhibition downregulated the expression of Bcl2 family of anti-apoptotic gene Bcl-xL. These observations suggest that STAT3 is required for the survival of CTCL cells and strongly indicate that targeting STAT3 using siRNA techniques may serve a novel therapeutic strategy for the treatment of CTCL.

show abstract

Section: Introductionmentioning

confidence: 99%

STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL

Verma

Davies

Long

et al. 2010

Cellular and Molecular Biology Letters

View full text Add to dashboard Cite

show abstract

“…Regarding patient convenience and cost-effectiveness, notable success has been achieved using single fraction doses of 7 to 8 Gy for local palliation with complete response rates of 94.4% [52]. In the study by Neelis, et al, a complete response rate of 92% was achieved using a dose of 8 Gy delivered in 2 fractions [53].…”

Section: Conflict Of Interestmentioning

confidence: 99%

Radiotherapy for Mycosis Fungoides: Review of the Literature

Sager¹,

Gamsiz²,

Dincoglan³

et al. 2017

J Dermatol Res Ther

View full text Add to dashboard Cite

show abstract

“…Lower doses (<30 Gy) were always associated with lower response to treatment (12,(18)(19)(20). In a study by Lindhal et al (18), 25 out of 35 patients received the high dose of 30 Gy, and 10 received the dose of 4 Gy.…”

Section: Discussionmentioning

confidence: 96%